Adenosine Antagonist Pipeline Insight
DelveInsight’s, “Adenosine Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Adenosine Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Adenosine Antagonists Understanding
Adenosine Antagonists: Overview
Adenosine is a naturally occurring nucleoside and an essential component of the energy production and utilization systems of the body. Adenosine is formed by the degradation of adenosine-triphosphate (ATP) during energy-consuming processes. Adenosine regulates numerous physiological processes through activation of four subtypes of G-protein coupled membrane receptors viz. A1, A2A, A2B and A3. Its physiological importance depends on the affinity of these receptors and the extracellular concentrations reached. ATP acts as a neurotransmitter in both peripheral and central nervous systems. Adenosine has been traditionally considered an inhibitor of neuronal activity and a regulator of cerebral blood flow. Since adenosine is neuroprotective against excitotoxic and metabolic dysfunctions observed in neurological and ocular diseases, the search for adenosinerelated drugs regulating adenosine transporters and receptors can be important for advancement of therapeutic strategies against these diseases.
"Adenosine Antagonists - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenosine Antagonists pipeline landscape is provided which includes the disease overview and Adenosine Antagonists treatment guidelines. The assessment part of the report embraces, in depth Adenosine Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenosine Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Adenosine Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Adenosine Antagonists.
Adenosine Antagonists Emerging Drugs Chapters
This segment of the Adenosine Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenosine Antagonists Emerging Drugs
AZD4635 is a novel, potent, small molecule, adenosine A2a receptor antagonist discovered by Sosei Heptare and licensed to AstraZeneca in 2015. The blockade of adenosine production in the tumor micro-environment is quickly emerging as one of the leading immuno-oncology treatment approaches and AZD4635 is one of the most advanced A2a receptor antagonists under investigation. AZD4635 is in a Phase II clinical trial for patients with metastatic castration resistant prostate cancer (mCRPC). AZD4635 is also being investigated in an ongoing Phase I clinic study in patients with Advanced Solid Malignancies.
AZD4635 has been designed to have a low molecular weight, good solubility and attractive drug-like properties coupled with high potency and selectivity, allowing it to be given at very high doses required to overcome the local high concentrations of adenosine.
Etrumadenant: Arcus Biosciences
Etrumadenant is a dual adenosine A2A and A2B receptor antagonists. Adenosine is a powerful immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain anti-tumor interventions, such as chemotherapy and radiation. The A2a/A2b receptors, expressed on the surface of immune cells, mediate the immunosuppressive effects of adenosine.It is currently in Phase II stage of development for the treatment of Non-small cell lung cancer and is being developed by Arcus Biosciences.
Further product details are provided in the report……..
Adenosine Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Adenosine Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Adenosine Antagonists
There are approx. 30+ key companies which are developing the therapies for Adenosine Antagonists. The companies which have their Adenosine Antagonists drug candidates in the most advanced stage, i.e. Phase II include, AstraZeneca.
DelveInsight’s report covers around 30+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Adenosine Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Adenosine Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Adenosine Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenosine Antagonists drugs.
Adenosine Antagonists Report Insights
- Adenosine Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Adenosine Antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Adenosine Antagonists drugs?
- How many Adenosine Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Adenosine Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Adenosine Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Adenosine Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?